XML 81 R64.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 29, 2023
Jun. 28, 2023
Feb. 28, 2023
May 17, 2022
Dec. 20, 2018
Dec. 31, 2023
Dec. 31, 2022
Oct. 24, 2023
Interest income           $ 662,859 $ 236,349  
Principal repayments           27,786 99,906  
Outstanding principal balance           1,570,886 $ 2,158,417  
General and administrative expenses           $ 164,859    
Common stock share issued           15,982,472 10,605,412  
Accrued interest           $ 166,348 $ 275,547  
Accounts receivable balance           19,759,254 23,691,997  
Prepaid expenses and other current assets - related party           1,811,911 1,546,225  
Revenue           53,376,874 50,347,652  
George Terzis [Member]                
Unpaid salaries and bonuses           98,000    
Common stock share issued               51,485
Basotho Investment Limited [Member]                
General and administrative expenses           $ 10,300    
Common stock share issued           120,000    
Grigorios Siokas [Member]                
Borrowing         $ 1,718,400      
Outstanding principal balance           $ 13,257 12,821  
Foreign curreny translation           436 64,729  
Accrued interest           0 206,355  
Interest rate         4.70%      
Maturity date         Mar. 18, 2019      
Cana Holdings Laboratories Holding Limited [Member]                
Secured promissory note     $ 4,457,520          
Description related to interest on principal     Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus one month LIBOR per annum (5.47% as of December 31, 2023)          
Interest income     $ 148,789          
DOC Pharma S.A. [Member]                
Interest income           217,476    
Principal repayments           442,480    
Interest repayments           $ 232,210    
Prepaid expenses             7,599,545  
Interest rate           5.50%    
Loan term           10 years    
Maturity date           Dec. 01, 2032    
Accounts payable and accrued expenses - related party           $ 34,217 201,991  
Prepaid balance           4,279,200    
Accounts receivable - related party           2,386,721 2,070,570  
Prepaid expenses and other current assets - related party           4,347,184 3,320,345  
Revenue           $ 619,637 1,058,780  
Agreement terminate           Dec. 31, 2025    
Pieces per product           1,000 pieces    
Purchased of additional licenses           $ 525,461    
Loan current portion           442,480 427,720  
Loan non-current portion           3,539,840 3,851,280  
Inventroy purchase           1,365,324 1,755,103  
Purchase of branded pharmaceuticals $ 3,539,840 $ 1,965,600            
Description of research and development       The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought a total of as of 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022        
Monthly basis instalments           35,660    
DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]                
Inventroy purchase           1,237,467 1,742,282  
Dimitrios Goulielmos [Member]                
Outstanding principal balance           11,283 10,912  
Foreign curreny translation           371 19,568  
Panagiotis Kozaris [Member]                
Shares owned           51,159 143,056  
Prepaid expenses           194,215 143,056  
Maria Kozari [Member]                
Accounts receivable balance           1,142,402 760,025  
Net sales           480,029 $ 463,467  
Kanarogloy & Sia Epe [Member]                
Accounts payable and accrued expenses - related party           $ 85,332